

Cullen M Taniguchi

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6248800/publications.pdf>

Version: 2024-02-01

137
papers

6,999
citations

159585

30
h-index

60623

81
g-index

151
all docs

151
docs citations

151
times ranked

11384
citing authors

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 1 | Neutralizing interleukin-6 in tumor-bearing mice does not abrogate behavioral fatigue induced by Lewis lung carcinoma. <i>Behavioural Brain Research</i> , 2022, 417, 113607. | 2.2 | 3 |
| 2 | Gastrointestinal malignancies and supportive care trials: a snapshot of the last two decades. <i>BMJ Supportive and Palliative Care</i> , 2022, 12, 42-45. | 1.6 | 2 |
| 3 | The radiotherapy quality assurance gap among phase III cancer clinical trials. <i>Radiotherapy and Oncology</i> , 2022, 166, 51-57. | 0.6 | 11 |
| 4 | Intraoperative Radiation After Pelvic Short Course Radiation-Based Total Neoadjuvant Therapy for Patients With Rectal Adenocarcinoma at High Risk for Local Recurrence. <i>Clinical Colorectal Cancer</i> , 2022, 21, 204-211. | 2.3 | 1 |
| 5 | Definitive Intensity-Modulated Chemoradiation for Anal Squamous Cell Carcinoma: Outcomes and Toxicity of 428 Patients Treated at a Single Institution. <i>Oncologist</i> , 2022, 27, 40-47. | 3.7 | 7 |
| 6 | Expansion of Candidate HPV-Specific T Cells in the Tumor Microenvironment during Chemoradiotherapy Is Prognostic in HPV16+ Cancers. <i>Cancer Immunology Research</i> , 2022, 10, 259-271. | 3.4 | 10 |
| 7 | NBTXR3, a first-in-class radioenhancer for pancreatic ductal adenocarcinoma: Report of first patient experience. <i>Clinical and Translational Radiation Oncology</i> , 2022, 33, 66-69. | 1.7 | 19 |
| 8 | Stromal HIF2 Regulates Immune Suppression in the Pancreatic Cancer Microenvironment. <i>Gastroenterology</i> , 2022, 162, 2018-2031. | 1.3 | 62 |
| 9 | The Therapeutic Potential of FLASH-RT for Pancreatic Cancer. <i>Cancers</i> , 2022, 14, 1167. | 3.7 | 8 |
| 10 | Feasibility of administering human pancreatic cancer chemotherapy in a spontaneous pancreatic cancer mouse model. <i>BMC Cancer</i> , 2022, 22, 174. | 2.6 | 3 |
| 11 | Exclusion of Older Adults from Cancer Clinical Trials: Review of the Literature and Future Recommendations. <i>Seminars in Radiation Oncology</i> , 2022, 32, 125-134. | 2.2 | 7 |
| 12 | Contemporary use and outcomes of radiation and chemotherapy for unresectable pancreatic cancer. <i>Clinical and Translational Radiation Oncology</i> , 2022, 35, 9-16. | 1.7 | 2 |
| 13 | Outcomes and Toxicities of Modern Combined Modality Therapy with Atezolizumab Plus Bevacizumab and Radiation Therapy for Hepatocellular Carcinoma. <i>Cancers</i> , 2022, 14, 1901. | 3.7 | 15 |
| 14 | Ablative liver radiotherapy for unresected intrahepatic cholangiocarcinoma: Patterns of care and survival in the United States. <i>Cancer</i> , 2022, 128, 2529-2539. | 4.1 | 7 |
| 15 | Microbiome Dynamics During Chemoradiation Therapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 113, 974-984. | 0.8 | 5 |
| 16 | Patient-Reported Bowel and Urinary Function in Long-Term Survivors of Squamous Cell Carcinoma of the Anus Treated With Definitive Intensity Modulated Radiation Therapy And Concurrent Chemotherapy. <i>International Journal of Radiation Oncology Biology Physics</i> , 2022, 114, 78-88. | 0.8 | 8 |
| 17 | ATR-mediated CD47 and PD-L1 up-regulation restricts radiotherapy-induced immune priming and abscopal responses in colorectal cancer. <i>Science Immunology</i> , 2022, 7, . | 11.9 | 52 |
| 18 | Impact of Fiducial Marker Placement Before Stereotactic Body Radiation Therapy on Clinical Outcomes in Patients With Pancreatic Cancer. <i>Advances in Radiation Oncology</i> , 2021, 6, 100621. | 1.2 | 10 |

| # | ARTICLE | IF | CITATIONS |
|----|--|-----|-----------|
| 19 | EUS-guided placement of fiducial markers for image-guided radiotherapy in gastrointestinal tumors: A critical appraisal. <i>Endoscopic Ultrasound</i> , 2021, . | 1.5 | 2 |
| 20 | Radiation-Associated Lymphopenia and Outcomes of Patients with Unresectable Hepatocellular Carcinoma Treated with Radiotherapy. <i>Journal of Hepatocellular Carcinoma</i> , 2021, Volume 8, 57-69. | 3.7 | 21 |
| 21 | Implementation of a stereotactic body radiotherapy program for unresectable pancreatic cancer in an integrated community academic radiation oncology satellite network. <i>Clinical and Translational Radiation Oncology</i> , 2021, 27, 147-151. | 1.7 | 0 |
| 22 | Development of an Objective Scoring System for Endoscopic Assessment of Radiation-Induced Upper Gastrointestinal Toxicity. <i>Cancers</i> , 2021, 13, 2136. | 3.7 | 0 |
| 23 | Clinical outcomes following definitive treatment of young-onset, locally advanced rectal cancer: A single institution experience.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15601-e15601. | 1.6 | 0 |
| 24 | Lack of pre-planned financial outcomes evaluation in phase 3 cancer trials.. <i>Journal of Clinical Oncology</i> , 2021, 39, e18826-e18826. | 1.6 | 0 |
| 25 | Association of the anorectal microbiome and patient-reported gastrointestinal outcomes in patients with anal cancer.. <i>Journal of Clinical Oncology</i> , 2021, 39, e15504-e15504. | 1.6 | 0 |
| 26 | Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.. <i>Journal of Clinical Oncology</i> , 2021, 39, 3112-3112. | 1.6 | 2 |
| 27 | CEA as a blood-based biomarker in anal cancer. <i>Oncotarget</i> , 2021, 12, 1037-1045. | 1.8 | 4 |
| 28 | Food and Drug Administration approvals in phase 3 Cancer clinical trials. <i>BMC Cancer</i> , 2021, 21, 695. | 2.6 | 7 |
| 29 | <i>ADAM10</i> Evens Out the Double-Edged Sword of Radiotherapy in Pancreatic Cancer. <i>Cancer Research</i> , 2021, 81, 3158-3159. | 0.9 | 1 |
| 30 | Impact factor and citation metrics in phase III cancer trials. <i>Oncotarget</i> , 2021, 12, 1780-1786. | 1.8 | 4 |
| 31 | Dosimetric Uncertainties Resulting From Interfractional Anatomic Variations for Patients Receiving Pancreas Stereotactic Body Radiation Therapy and Cone Beam Computed Tomography Image Guidance. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 1298-1309. | 0.8 | 12 |
| 32 | Elucidation of Tumor-Stromal Heterogeneity and the Ligand-Receptor Interactome by Single-Cell Transcriptomics in Real-world Pancreatic Cancer Biopsies. <i>Clinical Cancer Research</i> , 2021, 27, 5912-5921. | 7.0 | 57 |
| 33 | Comparative Untargeted Metabolomic Profiling of Induced Mitochondrial Fusion in Pancreatic Cancer. <i>Metabolites</i> , 2021, 11, 627. | 2.9 | 1 |
| 34 | A Machine Learning Model Approach to Risk-Stratify Patients With Gastrointestinal Cancer for Hospitalization and Mortality Outcomes. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, 135-142. | 0.8 | 8 |
| 35 | Biology of the Radio- and Chemo-Responsiveness in HPV Malignancies. <i>Seminars in Radiation Oncology</i> , 2021, 31, 274-285. | 2.2 | 13 |
| 36 | Sex differences in the behavioral and immune responses of mice to tumor growth and cancer therapy. <i>Brain, Behavior, and Immunity</i> , 2021, 98, 161-172. | 4.1 | 6 |

| # | ARTICLE | IF | CITATIONS |
|----|--|------|-----------|
| 37 | Stereotactic Versus Conventional Radiation Therapy for Patients With Pancreatic Cancer in the Modern Era. <i>Advances in Radiation Oncology</i> , 2021, 6, 100763. | 1.2 | 19 |
| 38 | Prognostic impact of lymphopenia and neutrophil-lymphocyte ratio for patients with anal squamous cell carcinoma. <i>Journal of Gastrointestinal Oncology</i> , 2021, 12, 2412-2422. | 1.4 | 4 |
| 39 | Benchmarking Outcomes for Definitive Treatment of Young-Onset, Locally Advanced Rectal Cancer. <i>Clinical Colorectal Cancer</i> , 2021, , . | 2.3 | 0 |
| 40 | Long-Term Patient-Reported Quality of Life and Functional Outcomes After Chemoradiation Using Intensity Modulated Radiotherapy for Anal Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2021, 111, S37-S38. | 0.8 | 1 |
| 41 | HIF2 Regulates Intestinal Wnt5a Expression. <i>Frontiers in Oncology</i> , 2021, 11, 769385. | 2.8 | 4 |
| 42 | APOBEC3A drives deaminase domain-independent chromosomal instability to promote pancreatic cancer metastasis. <i>Nature Cancer</i> , 2021, 2, 1338-1356. | 13.2 | 35 |
| 43 | Benchmarking Outcomes after Ablative Radiotherapy for Molecularly Characterized Intrahepatic Cholangiocarcinoma. <i>Journal of Personalized Medicine</i> , 2021, 11, 1270. | 2.5 | 3 |
| 44 | IMRT Reduces Acute Toxicity in Patients Treated With Preoperative Chemoradiation for Gastric Cancer. <i>Advances in Radiation Oncology</i> , 2020, 5, 369-376. | 1.2 | 5 |
| 45 | Exclusion of Older Adults in COVID-19 Clinical Trials. <i>Mayo Clinic Proceedings</i> , 2020, 95, 2293-2294. | 3.0 | 5 |
| 46 | Anal Adenocarcinoma: A Rare Malignancy in Need of Multidisciplinary Management. <i>JCO Oncology Practice</i> , 2020, 16, 635-640. | 2.9 | 12 |
| 47 | Applying to Radiation Oncology Amid a Pandemic. <i>Advances in Radiation Oncology</i> , 2020, 5, 777-779. | 1.2 | 1 |
| 48 | Characteristics of the Multiplicity of Randomized Clinical Trials for Coronavirus Disease 2019 Launched During the Pandemic. <i>JAMA Network Open</i> , 2020, 3, e2015100. | 5.9 | 19 |
| 49 | Professional Medical Writer Assistance in Oncology Clinical Trials. <i>Oncologist</i> , 2020, 25, e1812-e1815. | 3.7 | 5 |
| 50 | Randomized, Double-Blinded, Placebo-controlled Multicenter Adaptive Phase 1-2 Trial of GC 4419, a Dismutase Mimetic, in Combination with High Dose Stereotactic Body Radiation Therapy (SBRT) in Locally Advanced Pancreatic Cancer (PC). <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, 1399-1400. | 0.8 | 16 |
| 51 | Patient-Reported Outcome Measures in Pancreatic Cancer Receiving Radiotherapy. <i>Cancers</i> , 2020, 12, 2487. | 3.7 | 7 |
| 52 | Phase III Radiation Oncology Clinical Trials: A Snapshot of the Last Two Decades. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, e788-e789. | 0.8 | 0 |
| 53 | Outcomes with Proton and Photon Radiotherapy for Unresectable Hepatocellular Carcinoma. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E35-E36. | 0.8 | 0 |
| 54 | Clinical Associations of Treatment Failure After Radiation Therapy for Colorectal Liver Metastases. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E53-E54. | 0.8 | 0 |

| # | ARTICLE | IF | CITATIONS |
|----|---|------|-----------|
| 55 | How to Improve Enrollment Onto GI Radiation Oncology Clinical Trials: Lessons Learned From a Brachytherapy Trial for Newly Diagnosed Locally Advanced Pancreatic Cancer. <i>International Journal of Radiation Oncology Biology Physics</i> , 2020, 108, E55-E56. | 0.8 | 0 |
| 56 | Cancer Research after COVID-19: Where Do We Go from Here?. <i>Cancer Cell</i> , 2020, 37, 637-638. | 16.8 | 16 |
| 57 | Radiation therapy for patients with locally advanced pancreatic cancer: Evolving techniques and treatment strategies. <i>Current Problems in Cancer</i> , 2020, 44, 100607. | 2.0 | 17 |
| 58 | Microbiome factors in HPV-driven carcinogenesis and cancers. <i>PLoS Pathogens</i> , 2020, 16, e1008524. | 4.7 | 48 |
| 59 | Resolving the HIF paradox in pancreatic cancer. <i>Cancer Letters</i> , 2020, 489, 50-55. | 7.2 | 9 |
| 60 | Sponsor-Involved statistical analyses in Phase III cancer clinical trials. <i>International Journal of Cancer</i> , 2020, 147, 3579-3581. | 5.1 | 1 |
| 61 | Patient-Reported GI Outcomes in Patients With Anal Cancer Receiving Modern Chemoradiation. <i>JCO Oncology Practice</i> , 2020, 16, e1524-e1531. | 2.9 | 6 |
| 62 | Evaluation of the Visibility and Artifacts of 11 Common Fiducial Markers for Image Guided Stereotactic Body Radiation Therapy in the Abdomen. <i>Practical Radiation Oncology</i> , 2020, 10, 434-442. | 2.1 | 16 |
| 63 | Dose-Escalated Radiation Therapy for Pancreatic Cancer: A Simultaneous Integrated Boost Approach. <i>Practical Radiation Oncology</i> , 2020, 10, e495-e507. | 2.1 | 50 |
| 64 | Pathologic Response and Postoperative Complications After Short-course Radiation Therapy and Chemotherapy for Patients With Rectal Adenocarcinoma. <i>Clinical Colorectal Cancer</i> , 2020, 19, 116-122. | 2.3 | 1 |
| 65 | Performance status restriction in phase III cancer clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, 2059-2059. | 1.6 | 4 |
| 66 | A Mail Audit Independent Peer Review System for Dosimetry Verification of a Small Animal Irradiator. <i>Radiation Research</i> , 2020, 193, 341. | 1.5 | 5 |
| 67 | Performance Status Restriction in Phase III Cancer Clinical Trials. <i>Journal of the National Comprehensive Cancer Network: JNCCN</i> , 2020, 18, 1322-1326. | 4.9 | 18 |
| 68 | Enhanced microbial diversity and chemoradiation response in HPV+ anal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4-4. | 1.6 | 0 |
| 69 | Patient-reported gastrointestinal outcomes in patients with anal cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, 4055-4055. | 1.6 | 1 |
| 70 | The landscape of gastrointestinal oncologic phase III clinical trials in the last two decades.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14087-e14087. | 1.6 | 0 |
| 71 | Professional medical writing assistance in oncology clinical trials.. <i>Journal of Clinical Oncology</i> , 2020, 38, e14088-e14088. | 1.6 | 0 |
| 72 | Adaptive dose optimization trial of stereotactic body radiation therapy (SBRT) with or without GC4419 (avasopasem manganese) in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2020, 38, TPS4670-TPS4670. | 1.6 | 1 |

| # | ARTICLE | IF | CITATIONS |
|----|---|-----|-----------|
| 73 | Abstract 555: Mitochondrial fusion exerts KRAS-dependent therapeutic synergy with gemcitabine/nab-paclitaxel in preclinical models of pancreatic cancer. , 2020, , . | | 0 |
| 74 | Pancreatic cancer intratumoral microbiome and characteristics within paired patient samples.. Journal of Clinical Oncology, 2020, 38, 744-744. | 1.6 | 1 |
| 75 | Radiation Sciences Education in Africa: An Assessment of Current Training Practices and Evaluation of a High-Yield Course in Radiation Biology and Radiation Physics. JCO Global Oncology, 2020, 6, 1631-1638. | 1.8 | 7 |
| 76 | Fasting Reduces Intestinal Radiotoxicity, Enabling Dose-Escalated Radiation Therapy for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2019, 105, 537-547. | 0.8 | 33 |
| 77 | Assessment of setup uncertainty in hypofractionated liver radiation therapy with a breath-hold technique using automatic image registration-based image guidance. Radiation Oncology, 2019, 14, 154. | 2.7 | 8 |
| 78 | Can IMRT Reduce Lymphopenia in Patients Treated with Preoperative Chemoradiation for Gastric Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 103, E11. | 0.8 | 0 |
| 79 | Assessing for Enhanced Radiosensitivity in Hypoxic Tumors by Blocking Oxidative Phosphorylation Using IACS-010759. International Journal of Radiation Oncology Biology Physics, 2019, 103, E22. | 0.8 | 0 |
| 80 | Does Fiducial Marker Placement Prior to SBRT Increase the Risk of Metastatic Disease in Patients with Unresectable Pancreatic Cancer?. International Journal of Radiation Oncology Biology Physics, 2019, 103, E31. | 0.8 | 0 |
| 81 | Definitive hyperfractionated, accelerated proton reirradiation for patients with pelvic malignancies. Clinical and Translational Radiation Oncology, 2019, 19, 59-65. | 1.7 | 17 |
| 82 | Patient Setup Management for Pancreatic SBRT: Daily CT Based Assessment of Setup Accuracy using Vertebral Bone, Fiducial Markers, Biliary Stent, and Soft-Tissue Targeting. International Journal of Radiation Oncology Biology Physics, 2019, 105, E770. | 0.8 | 1 |
| 83 | EUS-guided placement of fiducial markers for the treatment of pancreatic cancer. VideoGIE, 2019, 4, 403-406. | 0.7 | 11 |
| 84 | Data Analytics Platform for Outcome Comparison of Patients Treated for Primary Pancreatic Cancer Using SBRT vs Conventional RT. International Journal of Radiation Oncology Biology Physics, 2019, 103, E51. | 0.8 | 0 |
| 85 | EUS-guided fiducial placement for GI malignancies: a systematic review and meta-analysis. Gastrointestinal Endoscopy, 2019, 89, 659-670.e18. | 1.0 | 33 |
| 86 | Novel EUS-guided brachytherapy treatment of pancreatic cancer with phosphorus-32 microparticles: first United States experience. VideoGIE, 2019, 4, 223-225. | 0.7 | 20 |
| 87 | Selective EGLN Inhibition Enables Ablative Radiotherapy and Improves Survival in Unresectable Pancreatic Cancer. Cancer Research, 2019, 79, 2327-2338. | 0.9 | 27 |
| 88 | Proton beam therapy outcomes for localized unresectable hepatocellular carcinoma. Radiotherapy and Oncology, 2019, 133, 54-61. | 0.6 | 37 |
| 89 | Enteral Activation of WR-2721 Mediates Radioprotection and Improved Survival from Lethal Fractionated Radiation. Scientific Reports, 2019, 9, 1949. | 3.3 | 13 |
| 90 | 923 Endoscopic Ultrasound-Guided Fiducial Placement for Stereotactic Body Radiation Therapy in Patients With Pancreatic Adenocarcinoma. American Journal of Gastroenterology, 2019, 114, S539-S540. | 0.4 | 0 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|-----|-----------|
| 91 | Circulating Nucleic Acids Are Associated With Outcomes of Patients With Pancreatic Cancer. <i>Gastroenterology</i> , 2019, 156, 108-118.e4. | 1.3 | 270 |
| 92 | Single-Cell Transcriptomics of Pancreatic Cancer Precursors Demonstrates Epithelial and Microenvironmental Heterogeneity as an Early Event in Neoplastic Progression. <i>Clinical Cancer Research</i> , 2019, 25, 2194-2205. | 7.0 | 268 |
| 93 | Mitochondrial fusion exploits a therapeutic vulnerability of pancreatic cancer. <i>JCI Insight</i> , 2019, 4, . | 5.0 | 102 |
| 94 | Adaptive Dose Escalation Trial of Stereotactic Body Radiation Therapy (SBRT) in combination with GC4419 in pancreatic cancer.. <i>Journal of Clinical Oncology</i> , 2019, 37, TPS4164-TPS4164. | 1.6 | 1 |
| 95 | The effect of IMRT on acute toxicity in patients with gastric cancer treated with preoperative chemoradiation.. <i>Journal of Clinical Oncology</i> , 2019, 37, 153-153. | 1.6 | 1 |
| 96 | Outcomes and patterns of failures after hypofractionated radiation therapy for intrahepatic cholangiocarcinoma.. <i>Journal of Clinical Oncology</i> , 2019, 37, e15609-e15609. | 1.6 | 0 |
| 97 | Abstract 3746: Fasting in mice enables abdominal radiation dose escalation in the setting of pancreatic cancer by mitigating small intestinal toxicity. , 2019, , . | | 0 |
| 98 | Abstract 1402: Single cell transcriptomic profiling of ex vivo tumoroid models reveal therapeutic vulnerabilities of pancreatic ductal adenocarcinoma. , 2019, , . | | 0 |
| 99 | A pilot course of intensive training in radiation biology and physics for oncologists in sub-Saharan Africa.. <i>Journal of Global Oncology</i> , 2019, 5, 24-24. | 0.5 | 0 |
| 100 | Abstract 3745: Mechanisms of HIF2-mediated small intestine radioprotection. , 2019, , . | | 0 |
| 101 | Imaging-based biomarkers: Changes in the tumor interface of pancreatic ductal adenocarcinoma on computed tomography scans indicate response to cytotoxic therapy. <i>Cancer</i> , 2018, 124, 1701-1709. | 4.1 | 35 |
| 102 | Locally Advanced/Unresectable Pancreatic Cancer. <i>Practical Guides in Radiation Oncology</i> , 2018, , 231-256. | 0.1 | 0 |
| 103 | Gastrointestinal-activated Amifostine Ameliorates Morbid Toxicity from Stereotactic Radiation in a Murine Model. <i>International Journal of Radiation Oncology Biology Physics</i> , 2018, 102, S76. | 0.8 | 0 |
| 104 | Dose escalation for locally advanced pancreatic cancer: How high can we go?. <i>Advances in Radiation Oncology</i> , 2018, 3, 693-700. | 1.2 | 30 |
| 105 | Stem cell enriched-epithelial spheroid cultures for rapidly assaying small intestinal radioprotectors and radiosensitizers in vitro. <i>Scientific Reports</i> , 2018, 8, 15410. | 3.3 | 13 |
| 106 | Dose escalation of radiotherapy in unresectable extrahepatic cholangiocarcinoma. <i>Cancer Medicine</i> , 2018, 7, 4880-4892. | 2.8 | 23 |
| 107 | Treatment of primary rectal adenocarcinoma after prior pelvic radiation: The role of hyperfractionated accelerated reirradiation. <i>Advances in Radiation Oncology</i> , 2018, 3, 595-600. | 1.2 | 4 |
| 108 | A Visually Apparent and Quantifiable CT Imaging Feature Identifies Biophysical Subtypes of Pancreatic Ductal Adenocarcinoma. <i>Clinical Cancer Research</i> , 2018, 24, 5883-5894. | 7.0 | 76 |

| # | ARTICLE | IF | CITATIONS |
|-----|--|------|-----------|
| 109 | Hyperfractionated abdominal reirradiation for gastrointestinal malignancies. Radiation Oncology, 2018, 13, 143. | 2.7 | 9 |
| 110 | Dose escalation with an IMRT technique in 15 to 28 fractions is better tolerated than standard doses of 3DCRT for LAPC. Advances in Radiation Oncology, 2017, 2, 403-415. | 1.2 | 29 |
| 111 | Hypoxia inducible factor (HIF) in the tumor microenvironment: friend or foe?. Science China Life Sciences, 2017, 60, 1114-1124. | 4.9 | 96 |
| 112 | Definitive radiation therapy for hepatocellular carcinoma with portal vein tumor thrombus. Clinical and Translational Radiation Oncology, 2017, 4, 39-45. | 1.7 | 11 |
| 113 | Short course radiation as a component of definitive multidisciplinary treatment for select patients with metastatic rectal adenocarcinoma. Journal of Gastrointestinal Oncology, 2017, 8, 990-997. | 1.4 | 19 |
| 114 | Bi-directional regulation of brown fat adipogenesis by the insulin receptor.. Journal of Biological Chemistry, 2016, 291, 27434. | 3.4 | 2 |
| 115 | Identification of KIAA1199 as a Biomarker for Pancreatic Intraepithelial Neoplasia. Scientific Reports, 2016, 6, 38273. | 3.3 | 24 |
| 116 | Divergent Regulation of Hepatic Glucose and Lipid Metabolism by Phosphoinositide 3-Kinase via Akt and PKC δ /I κ B. Cell Metabolism, 2016, 23, 386. | 16.2 | 2 |
| 117 | It α 's a SMAD/SMAD World. Cell, 2015, 161, 1245-1246. | 28.9 | 5 |
| 118 | Suppression of PGC-1 β Is Critical for Reprogramming Oxidative Metabolism in Renal Cell Carcinoma. Cell Reports, 2015, 12, 116-127. | 6.4 | 140 |
| 119 | PHD Inhibition Mitigates and Protects Against Radiation-Induced Gastrointestinal Toxicity via HIF2. Science Translational Medicine, 2014, 6, 236ra64. | 12.4 | 120 |
| 120 | Initial Experience with Electronic Brachytherapy for Skin Cancer: Clinical and Dosimetric Characteristics. Brachytherapy, 2014, 13, S107. | 0.5 | 1 |
| 121 | Cross-talk between hypoxia and insulin signaling through Phd3 regulates hepatic glucose and lipid metabolism and ameliorates diabetes. Nature Medicine, 2013, 19, 1325-1330. | 30.7 | 125 |
| 122 | A liver Hif-2 β -Irs2 pathway sensitizes hepatic insulin signaling and is modulated by Vegf inhibition. Nature Medicine, 2013, 19, 1331-1337. | 30.7 | 90 |
| 123 | Dosimetric Analysis of Organs at Risk During Expiratory Gating in Stereotactic Body Radiation Therapy for Pancreatic Cancer. International Journal of Radiation Oncology Biology Physics, 2013, 85, 1090-1095. | 0.8 | 50 |
| 124 | Bone morphogenetic protein 7 (BMP7) reverses obesity and regulates appetite through a central mTOR pathway. FASEB Journal, 2012, 26, 2187-2196. | 0.5 | 93 |
| 125 | Insulin/IGF-1 Signaling Nodes and their Role in Carcinogenesis. Energy Balance and Cancer, 2011, , 53-76. | 0.2 | 2 |
| 126 | The Phosphoinositide 3-Kinase Regulatory Subunit p85 β Can Exert Tumor Suppressor Properties through Negative Regulation of Growth Factor Signaling. Cancer Research, 2010, 70, 5305-5315. | 0.9 | 140 |

| # | ARTICLE | IF | CITATIONS |
|-----|---|------|-----------|
| 127 | Role of atypical protein kinase C in activation of sterol regulatory element binding protein-1c and nuclear factor kappa B (NF κ B) in liver of rodents used as a model of diabetes, and relationships to hyperlipidaemia and insulin resistance. <i>Diabetologia</i> , 2009, 52, 1197-1207. | 6.3 | 54 |
| 128 | New role of bone morphogenetic protein 7 in brown adipogenesis and energy expenditure. <i>Nature</i> , 2008, 454, 1000-1004. | 27.8 | 964 |
| 129 | The p85 β Regulatory Subunit of Phosphoinositide 3-Kinase Potentiates c-Jun N-Terminal Kinase-Mediated Insulin Resistance. <i>Molecular and Cellular Biology</i> , 2007, 27, 2830-2840. | 2.3 | 74 |
| 130 | Divergent regulation of hepatic glucose and lipid metabolism by phosphoinositide 3-kinase via Akt and PKC δ . <i>Cell Metabolism</i> , 2006, 3, 343-353. | 16.2 | 249 |
| 131 | Critical nodes in signalling pathways: insights into insulin action. <i>Nature Reviews Molecular Cell Biology</i> , 2006, 7, 85-96. | 37.0 | 2,299 |
| 132 | Phosphoinositide 3-kinase regulatory subunit p85 β suppresses insulin action via positive regulation of PTEN. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2006, 103, 12093-12097. | 7.1 | 149 |
| 133 | Prediction of preadipocyte differentiation by gene expression reveals role of insulin receptor substrates and neclin. <i>Nature Cell Biology</i> , 2005, 7, 601-611. | 10.3 | 202 |
| 134 | Synthesis of E-vinylogous (R)-amino acid derivatives via metal-catalyzed allylic substitutions on enzyme-derived substrates. <i>Tetrahedron: Asymmetry</i> , 2005, 16, 1655-1661. | 1.8 | 22 |
| 135 | Complementary roles of IRS-1 and IRS-2 in the hepatic regulation of metabolism. <i>Journal of Clinical Investigation</i> , 2005, 115, 718-727. | 8.2 | 237 |
| 136 | A Two-Step Procedure for the Conversion of α,β -Unsaturated Aldehydes into β -Azido- α,β -Unsaturated Nitriles. <i>Journal of Organic Chemistry</i> , 2001, 66, 7191-7194. | 3.2 | 35 |
| 137 | Chiral induction in cyclopentyl-derived 1,3-meso-diester: enantioselective hydrolyses with electric eel acetylcholinesterase. <i>Tetrahedron: Asymmetry</i> , 1999, 10, 2139-2152. | 1.8 | 9 |